Partial dysferlin reconstitution by adult murine mesoangioblasts is sufficient for full functional recovery in a murine model of dysferlinopathy by Díaz-Manera, J et al.
Partial dysferlin reconstitution by adult murine
mesoangioblasts is sufﬁcient for full functional
recovery in a murine model of dysferlinopathy
JD ı ´az-Manera
1,2,3, T Touvier
1, A Dellavalle
1, R Tonlorenzi
1, FS Tedesco
1, G Messina
1,4, M Meregalli
5, C Navarro
5, L Perani
1,
C Bonfanti
1, I Illa
2,3, Y Torrente
5 and G Cossu*
,1,4
Dysferlin deﬁciency leads to a peculiar form of muscular dystrophy due to a defect in sarcolemma repair and currently lacks
a therapy. We developed a cell therapy protocol with wild-type adult murine mesoangioblasts. These cells differentiate with high
efﬁciency into skeletal muscle in vitro but differ from satellite cells because they do not express Pax7. After intramuscular
or intra-arterial administration to SCID/BlAJ mice, a novel model of dysferlinopathy, wild-type mesoangioblasts efﬁciently
colonizeddystrophicmusclesandpartiallyrestoreddysferlinexpression.Nevertheless,functionalassaysperformedonisolated
single ﬁbers from transplanted muscles showed a normal repairing ability of the membrane after laser-induced lesions; this
result, which reﬂects gene correction of an enzymatic rather than a structural deﬁcit, suggests that this myopathy may be easier
to treat with cell or gene therapy than other forms of muscular dystrophies.
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Mutations in the human dysferlin gene (DYSF) cause an
autosomalrecessivemusculardystrophywithdifferentclinical
phenotypes: limb girdle muscular dystrophy (LGMD-2B),
distal posterior myopathy or Miyoshi’s myopathy, distal
anterior myopathy, asymptomatic hyperckemia and the
recently described, congenital muscular dystrophy.
1–3
Generally, the ﬁrst symptoms appear in the late teens or
early in adulthood.
4 The rate of progression is variable,
although the majority of patients develop a severe clinical
situation characterized by inability to walk without support or
conﬁnement to a wheelchair within 10–20 years from the
onset of symptoms.
5
Two different naturally occurring murine models with
mutations in the dysferlin gene have been described: the
A/J and SJL lines.
6 The genetic modiﬁcation of the A/J strain
consists in a unique ETn retrotransposon insertion near the
50 end (intron 4) of the dysferlin gene producing the complete
loss of the protein.
6 A/J mice develop a late-onset and slowly
progressive muscular disease. The ﬁrst dystrophic features
appear at 4–5 months, affecting both lumbar and proximal
muscles of the lower limbs. By 9 months of age, dystrophic
muscles present variation in ﬁber size, moderate fatty
inﬁltration and sparse necrotic ﬁbers surrounded by macro-
phages inﬁltrates.
7
The function of dysferlin in skeletal muscle is related to
membrane repair. It has been shown that dysferlin is required
for the fusion of intracellular vesicles to the membrane
and consequent resealing of the sarcolemma after external
damage.
8 In support of this hypothesis, nonfused intracellular
vesicles near the surface of the muscular ﬁbers have been
described in biopsies from affected patients.
9 Moreover, no
recovery of sarcolemma integrity was observed after laser-
induced lesions in the membrane of isolated single ﬁbers from
dysferlin-deﬁcient mice.
10,11
Mesoangioblasts (MABs) are vessel-associated progeni-
tors
12 that can be isolated from different embryonic and adult
tissues, expanded in vitro, easily transduced with lenti-
viral vectors and have the ability to cross the vessel wall
when injected into the bloodstream.
13 Intra-arterial delivery
of murine and canine MABs, respectively, ameliorated the
dystrophic phenotype of Sgca null mice (a murine model
of LGMD-2D) and of Golden Retriever dogs affected by
a dystrophin deﬁcit (a natural occurring model of Duchenne
muscular dystrophy (DMD)).
14,15 Similar cells isolated from
human postnatal skeletal muscle were shown to represent a
subset of pericytes and were able to give rise to dystrophin-
positive muscle ﬁbers when transplanted into scid/mdx
mice.
16 Based on these studies, a phase I clinical trial with
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In this study, we isolated and characterized MABs from
muscular biopsies of adult C57BL/6 w i l d - t y p em i c e( C 5 7 - J 1
cells).Thesecellssharedseveralcharacteristicswithpreviously
describedembryonicmouseMABs(e.g.,theD16cells),suchas
the ability to differentiate into other mesenchymal tissues or the
capacity to cross the vessel wall and colonize dystrophic
muscles after intra-arterial injection. However, at variance with
D16 cells, and similar to human postnatal MABs, C57-J1 cells
spontaneously differentiate into skeletal myotubes with high
efﬁciency; yet they differ from bona ﬁde satellite cells (SCs)
for the absence of Pax7 expression. Here we show that
after transplantation into the dysferlin-deﬁcient murine model
SCID/BlAJ, C57-J1 cells were able to fuse with muscle ﬁbers,
restoring the expression of dysferlin and causing normalization
of the resealing capacity of the plasma membrane.
Results
Characterization of adult murine-derived MABs (C57-J1).
Adult-derived MABs were isolated from the tibialis anterior of
a 2-month-old C57BL/6 female mouse.
17 When cultured in
proliferation medium (PM), they showed a small, refractile
morphology and proliferated rapidly, with a doubling time of
approximately 24h (Figure 1a). During proliferation, virtually all
cells expressed at high level the surface markers Sca-1 and
CD44 (Supplementary Figure 1) but, in contrast to SCs, they did
not express detectable levels of MyoD or Pax7 (Figure 1e and f).
Unexpectedly, they did not express alkaline phosphatase (AP)
(Supplementary Figure 2a) similar to their human counterparts.
18
Once conﬂuent, they progressively differentiated into
striated muscle (Figure 1b). On average, 25–40% of cells
fused into striated, myosin-positive, multinucleated myotubes
(Figure 1c and d). Myogenic differentiation was not inﬂuenced
by the substratum (Matrigel versus plastic: Supplementary
Figure 2d). The myogenic transcription factors MyoD and
Myogenin were robustly expressed only after 48h in
differentiation medium, at the onset of myotube formation,
andunderwenta progressivereduction inthe expressionlevel
afterday4(Figure1e).Theexpressionofdysferlinwasclearly
detectable in myotubes concomitant with MyoD expression
(Figure1e).Itsconcentrationincreasedprogressivelypeaking
up at days 6 and 8, concomitant with the maximum fusion of
mononucleated cells into myotubes (Figure 1c and e).
Despite their spontaneous myogenic differentiation
potency, C57-J1 cells were also able to differentiate in vitro
into other mesoderm tissues upon exposure to proper induc-
tive signals, as previously described for other MAB lines. After
treatment with bone morphogenic protein-2 (BMP-2), they
expressed AP whereas they expressed smooth muscle actin
when treated with transforming growth factor-b (TGF-b);
moreover, after 6 days of culture into adipogenic medium,
rounded intracellular oil-red-positive vesicles were detected.
(Supplementary Figures 2a–c).
Engraftment failure in A/J mice and generation of A/J
SCID strain. To investigate the ability of adult-derived murine
MABs to restore the expression of dysferlin in dystrophic
muscles, we injected 5 10
5 C57-J1 cells, previously trans-
duced with lentiviral vector expressing nuclear LacZ, into the
tibialis anterior and quadriceps of 5-month-old Bl/AJ mice
(n¼7) (generous gift from I Richard, Ge ´ne ´thon). At 36h after
the injection, numerous nuclear LacZ (nLacZ)-positive cells
were detected in the muscles, but they appeared already
surrounded by an inﬂammatory inﬁltrate composed by
neutrophils, CD68þ macrophages and CD3þ T lymphocytes
(Figure 2a). The inﬂammatory inﬁltrate increased progressively
until day 7, when numerous CD68þ cells were localized
in the injection area, but also in distant areas of the muscle and
in the vessel walls (data not shown). By day 12 we detected
some degenerating muscle ﬁbers with LacZ-positive nuclei
surrounded by CD68þ and CD3þ cells (Figure 2b). At
3 weeks after the injection muscle regeneration was
completed, probably at the expense of resident SCs
because no LacZ-positive cells could be detected either
inside or outside ﬁbers, whereas some CD68 and CD3 cells
remained in the perymysium (Figure 2a). This result may
depend upon the altered immune response of Bl/AJ mice
characterized by a more aggressive phagocytic activity of
macrophages and a reduced expression of decay-accele-
rating factor (DAF) in muscles.
19,20 Because of these results,
we decided to generate a dystrophic, immune-deﬁcient mouse
by crossing Bl/AJ mice onto an SCID mice background (SCID
BL/AJ). The F4 generation used in this study showed absence
of mature T and B lymphocytes by FACS analyses (data
not shown) and the presence of retrotransposon insertion
in dysferlin gene, as originally described in the A/J strain by
Ho et al.
6 At 5 months of age, A/J SCID and Bl/AJ mice
showed dystrophic changes, such as central nuclei, ﬁber
splitting, variation on ﬁber size and presence of regenerating
ﬁbers (Supplementary Figure 3a). Azan Mallory staining
showed a similar degree of ﬁbrosis in both AJ/SCID and
Bl/AJ model compared to the control (Supplementary Figure 3a).
As expected, immunoﬂuorescence (IF) analysis and reverse
transcription (RT)-PCR staining conﬁrmed the absence of
dysferlin expression (Supplementary Figure 3b and c).
Restoration of dysferlin expression by injection of
C57-J1 cells into the new SCID/BlAJ line. We tested the
ability of C57-J1 cells to restore the expression of dysferlin in
muscles from the SCID/BlAJ mice. We performed a single
intramuscular injection of 5 10
5 nLacZ labeled C57-J1 cells
in untreated or cardiotoxin (ctx)-pretreated tibialis anterior,
quadriceps and gastrocnemius of 5-month-old SCID/BlAJ
mice (n¼ 6 mice, 3 pretreated with ctx). ctx was used to
exacerbate the pathology of these mice that at 5 months
show a less severe phenotype than other strains such as
the a-sarcoglycan null mice, previously used for MAB trans-
plantation.
13 At 1 month after the injection, numerous nLacZ-
positive ﬁbers were detected in transverse muscle sections
at different craniocaudal levels (Figure 3a); although nLacz-
positive ﬁbers were diffuse in the ctx-treated muscles,
they were more concentrated near the injection area in the
untreated muscles. In parallel, we performed a single intra-
arterial injection of 5 10
5 nLacZ labeled C57-J1 cells
into the right femoral artery of untreated and ctx-treated,
5-month-old SCID/BlAJ mice (n¼10, 5 pretreated with ctx).
To increase susceptibility of muscles to engraftment by
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Cell Death and DiseaseC57-J1 cells, we trained all mice with 1h swimming 24h
before the transplantation. We found LacZ-positive cells in all
muscles situated downstream of injection site (Figure 3a and
Supplementary Figure 4). The number of LacZ-positive cells
was higher in ctx-treated muscles, but LacZ ﬁbers were
clearly detected also in untreated muscles (a quantiﬁcation is
Figure 1 Characterization of C57-J1 cells. Phase-contrast microscopy of adult-derived C57-J1 MABs revealing a small, refractile, triangular shape (a). Once conﬂuent,
cellsprogressivelydifferentiatedintomultinucleatedmyotubes(bshowscellsafter8daysindifferentiationmedium).Atthisstage,IFrevealsthatexpressionofstriatedmyosin
(c,top)anddysferlin(c,middle)colocalizedinmyotubes(c,bottom).Differentiationindex,calculatedastheproportionoftotalnucleiexpressingMHC,rangedbetween25and
40% (d). Western blot analysis performed at different points during differentiation to striated muscle showing concomitant presence of MyoD, myogenin and dysferlin (e).
During proliferation status C57-J1 cells did not express MyoD and Pax7 as in satellite cells (e and f)
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Cell Death and Diseasereported in Figure 3b). Real-time PCR detected statistically
signiﬁcant expression of dysferlin in all muscles treated
using both intramuscular or intra-arterial delivery of cells
(Figure 3c). When injected intramuscularly, the average level
of dysferlin ranged between 17 and 27% of wild-type muscle
levels in the ctx-pretreated muscles (maximum of 35% in the
gastrocnemius), and between 12 and 15% in the non-ctx-
treated (maximum of 28% in the tibialis anterior of one of the
animals). A single intra-arterial injection of cells was sufﬁcient
to achieve signiﬁcant expression of dysferlin in all muscles
analyzed. The average level in this case varied between 9
and 11% of wild-type muscles in the ctx-pretreated animals
(maximum of 16% in the gastrocnemius of one animal) and
between 6 and 12% in the non-ctx-treated animals (maxi-
mum of 18% in the quadriceps of one mouse). Dysferlin
was detected in many ﬁbers that invariably contained
b-galactosidase-positive nuclei; the protein was absent in
noninjected muscles (Figure 4a). Western blot (WB) analysis
Figure 2 Inﬂammatory inﬁltrates surrounded transplanted cells in BlAJ mice. Hematoxylin-eosin staining of transplanted muscles, showing intense inﬂammatory reaction
after intramuscular injection of 5 10
5 nLacZ-positiveC57-J1 cells into tibialis anterior of 5-month-old BlAJ mice (a, left column). Note almost normal muscle architectureand
inﬁltrateresolution21daysaftertheinjection.X-galstainingontransplantedmusclesshowingaprogressivelossofLacZ-positivecells(a,middleleftcolumn).Immunestaining
withanti-CD3andanti-CD68antibodiesdetectedamixedpopulationofTlymphocytesandmacrophagescomposingtheinﬁltrate(a,middlerightandrightcolumn).Numerous
X-gal-positive muscle ﬁbers invaded by CD3- and CD68-positive cells were detected (b, yellow arrow) whereas X-gal negative ﬁbers maintained its basal lamina intact
(b, white arrow)
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Cell Death and DiseaseFigure 3 C57-J1 cells successfully colonized muscles of SCID/BlAJmice. X-gal staining of SCID/BlAJtibialis anterior 1 month after a single intramuscular or intra-arterial
injection of 5 10
5 C57-J1 cells, previously labeled with nLacZ. At 1 month after the injection numerous LacZ-positive muscle ﬁbers were observed (Figure 3a), localized
throughout the entire area of the muscle section. Quantiﬁcation of LacZ-positive ﬁbers in tibialis anterior and gastrocnemius (Figure 3b): dysferlin mRNA was detected at
signiﬁcant higher levels in transplanted than in nontransplanted muscles in all conditions performed (c, tibialis anterior, quadriceps and gastrocnemius). Differences were
analyzed using Student’s t-test and considered signiﬁcant if Po0.05. Bars show mean values, with standard error. Im, intramuscular; Ia, intra-arterial; Ctx, cardiotoxin
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Cell Death and Diseaseconﬁrmed the ﬁndings of the real-time PCR and showed
expression of the dysferlin protein in all transplanted dys-
trophic muscles, with a higher level in muscles previously
treated with ctx (Figure 4b).
Functional assays. Five-month-old SCID mice (n¼3),
control nontransplanted SCID/BlAJ mice (n¼4) and SCID/
BlAJ intra-arterially transplanted with C57-J1 cells (n¼4)
were tested for motor activity on the treadmill. All dystrophic
untreated SCID/BlAJ showed worse performance in this
test than control SCID mice but differences were not
statistically signiﬁcant at this age. Motility of transplanted
SCID/BlAJ improved notably compared with untreated
mice, but differences did not reach statistical signiﬁcance
(Supplementary Figures 5a–c). Increase in creatine kinase
levels after the exercise was detected in all animals, but it
was lower in the treated than in the nontreated SCID/BlAJ
mice, without statistical signiﬁcance (data not shown).
Theabsenceofsigniﬁcantdifferencesintreadmillprompted
us to use another, possibly more sensitive, functional assay.
As dysferlin absence causes a defect in membrane repair,
we tested the ability of single ﬁbers from transplanted mice
to reseal the membrane after a focal damage produced
by a laser, as previously described by Bansal et al.
10
We administered a single injection of 5 10
5 GFP-labeled,
C57-J1 cells into tibialis anterior, extensor digitorum longus
and gastrocnemius of 5-month-old SCID/BlAJ mice. At
1 month after the injection, GFP was easily detected in all
injected muscles (Figure 5a) but not in noninjected, contra-
lateral muscles. Single ﬁbers from control SCID mice (n¼4),
untreated SCID/BlAJ (n¼4) and transplanted SCID/BlAJ
mice (n¼4) were isolated and plated into dishes with Ca
2þ
PBS. Dysferlin was detected only in the surface of GFP-
positiveﬁbersinapatchydistribution(Figure5b).Singleﬁbers
were irradiated with a laser in the presence of the ﬂuores-
cence dye FM 4-64 to create a lesion in the plasma
Figure 4 Transplantation of C57-J1cells into the SCID/BlAJ murine model successfully restored the expression of dysferlin. Immunoﬂuorescence with anti-dysferlin
antibodiesdetectingtheproteinonlyonthemembraneofb-galactosidase-positiveﬁbers(a).Westernblotanalysisofmusclelysatesshowingthepresenceofdysferlinprotein
in all conditions studied (b)
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Cell Death and Diseasemembrane. In this experimental model, increase in the
ﬂuorescence signal in the area adjacent to the sarcolemmal
lesion inversely correlates with the resealing activity of
the membrane; in fact, the increase in signal intensity
rapidly stops in wild-type, dysferlin-positive ﬁbers whereas
it continues to augment in the dysferlin negative ﬁbers.
10
The increase in the signal was much lower in the MABs-
transplanted ﬁbers from the SCID/BlAJ mice than from the
nontreated mice (Po0.0001) and, importantly, this increase
was not different from the one detected in single ﬁbers
from wild-type control mice (Figure 5c and d).
Discussion
New therapies for muscular dystrophies. Muscular dys-
trophies still lack an efﬁcacious therapy. In preclinical
models, cell transplantation, gene therapy, exon skipping
and molecules inducing muscle hypertrophy all produced
encouraging results but await the results of controlled clinical
experimentation.
Ourlaboratorypioneeredprogenitorcelltransplantationina
murine (a-sarcoglycan deﬁciency) and in a canine (dystrophin
deﬁciency) model of muscular dystrophy. The success of the
transplantationdependsuponanumberofparametersamong
which the histopathology of the transplanted muscle, the
presence of a resident myogenic population and the engraft-
ment and myogenic potency of the donor cells appear the
most important. For example, in the mdx mouse, which has
vigorous endogenous regeneration, embryonic D16 MAB
transplantation produced modest engraftment and dystrophin
production (M Sampaolesi and G Cossu, unpublished data). It
thus becomes very important to test the cell therapy protocol
in other forms of muscular dystrophy, possibly using a
robustly myogenic MAB population, given the fact that the
D16 embryonic MABs have a modest intrinsic myogenic
potency.
Adult MABs have robust myogenic potency. To this aim,
we have isolated and characterized MABs from skeletal
muscles of adult mice. Although these cells have the ability to
differentiate into diverse types of mesoderm cell types, they
show a robust myogenic differentiation both in vitro and, most
importantly, when injected intramuscularly or intra-arterially
in dystrophic muscle. The MABs obtained from murine adult
skeletal muscle biopsies are distinguishable from SCs as
they do not express CD34, MyoD or Pax7 during proli-
feration, although they activate MyoD when myogenesis is
Figure 5 Functional assays. GFP expression pattern of dystrophic tibialis anterior of 5-month-old SCID/BlAJ 1 month after the intramuscular injection of 5 10
5
GFP-positive C57-J1 cells (a). Immunoﬂuorescence analysis showing dysferlin expression on the membrane of GFP-positive single ﬁbers in a patchy distribution (b, white
arrows). Membrane repair assay was performed in isolated single ﬁbers from WT, SCID (c, top panel), nontransplanted SCID/BlAJ (c, middle panel) and transplanted SCID/
BlAJ (c, bottom panel) mice. Note a larger area of dye staining in the nontreated SCID/BlAJ ﬁbers after laser-induced lesions (c). Measurement of ﬂuorescence intensity
versus time is shown in d for WT (blue line), nontransplanted SCID/BlAJ (red line) and transplanted SCID/BlAJ (green line) showing signiﬁcant higher levels in the
nontransplanted SCID/BlAJ. There were no differences between transplanted SCID/BlAJ and WT mice. Data are mean±S.E. (WT n:10 ﬁbers, nontreated SCID/BlAJ n:15
ﬁbers, transplanted SCID/BlAJ n:20 ﬁbers); statistical analysis was carried out with Student’s t-test and ANOVA test for repeated measurements. Po0.05 was considered
signiﬁcant
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Cell Death and Diseaseinduced.
21 Surprisingly, AP is not expressed by these cells in
culture, at variance with human MABs. In murine muscles,
AP is expressed in vivo by pericytes and by endothelial cells,
but this expression is lost after serial passages in culture.
Dysferlin was expressed by C57-J1 cells and also by human-
derived MABs when differentiated into skeletal muscle
(J Dı ´az-Manera and G Cossu, unpublished data).
Adult MABs repair the dysferlinopathy in the mouse. We
showed expression of dysferlin in b-galactosidase-positive
ﬁbers after nLacZ-positive MAB transplantation in the SCID/
BlAJ mice, and because revertant ﬁbers have not been
reported in the A/J mice, dysferlin detected by IF or WB
should have been produced from transplanted cells once
fused with dystrophic ﬁbers. The A/J mutation results in a
drastic reduction of dysferlin mRNA (o2–4% of wild-type
muscle). After transplantation, dysferlin mRNA was detected
in muscles at much higher levels, up to 35% of wild-type
levels after a single intramuscular injection, and 18% after a
single intra-arterial injection. It has been previously reported
that the levels of dysferlin can be reduced in asymptomatic or
mildly symptomatic carriers of the disease.
22 WB of muscles
from heterozygous familiars of affected patients showed
dysferlin expression of 40–50% compared to control levels.
23
Moreover, a recent analysis of the dysferlin protein levels in
CD14þ monocytes from peripheral blood, which correlates
with levels in skeletal muscle, showed reduced expression in
60% of asymptomatic carriers, than in some cases reached
up to 80% of reduction compared to normal controls.
24 Thus
a partial reconstitution of dysferlin, to the levels detected in
this study after a single injection, should be sufﬁcient to
reduce signiﬁcantly or even eliminate symptoms in affected
patients.
Although myoblast transplantation had previously resulted
in dysferlin expression in the tibialis anterior of SJL dystrophic
mice,
25 no analysis of functional improvement was reported
and, moreover, myoblast transplantation is limited to topic
intramuscular delivery. In our study, we observed functional
differences with the treadmill test, but they did not reach
statistical signiﬁcance likely because of the modest difference
between dystrophic and control mice in this speciﬁc model.
To conclusively show a functional recovery in transplanted
mice, we used and assay previously described by Bansal
et al.
10 that is based upon laser-induced membrane lesion.
This method has recently been used to analyze response
to different gene therapy strategies and is very sensitive
in detecting functional recovery of dysferlin null mice treated
with gene or stem cell therapy.
26 In our case, transplantation
was followed by normal resealing activity of isolated single
ﬁbers from MAB-transplanted SCID/BlAJ mice, compared
to the nontransplanted ﬁbers. These results, in agreement
with the reduced expression of dysferlin in asymptomatic
carriers, indicate that normal levels are not necessary to
obtain a complete resealing activity of the plasma membrane.
Dysferlin has not a structural role in the muscle ﬁber as
dystrophin or sarcoglycans; its activity is related to repairing
of the membrane and, thus, much as it happens with proteins
endowed with an enzymatic function in metabolic diseases,
a partial restoration of expression would be sufﬁcient for a
virtually complete functional recovery.
The immune response obtained in the nonimmuno-
suppressed Bl/AJ muscles after transplantation of C57-J1
cells has been also described after myoblast transplantation
in nonimmunosuppressed mice,
27 and might be exacerbated
in this case by the expression of b-galactosidase by the cells
and by the altered immune system of the dysferlin-deﬁcient
mice. It is known that dysferlin-deﬁcient monocytes and
macrophages show abnormally high phagocytic activity.
20
Moreover, the expression of DAF (or CD55), a molecule that
has been related with suppression of complement activation
andinhibitionoftheinteractionofantigen-presentingcellswith
T lymphocytes has been shown to be reduced in dysferlin-
deﬁcient muscles.
19 Accordingly to this, a lower expression
of DAF by grafts has been related with accelerated T-cell-
mediated rejection in renal or heart transplants.
28,29 There-
fore,apermanentimmunesuppressionwouldbenecessaryin
a hypothetical transplantation of human MABs in patients
affected by this form of muscular dystrophy.
Cell transplantation at an early stage of the disease. To
optimize therapeutic results, we decided to treat dystrophic
mice in a paucisymptomatic stage, before the presence
of abundant ﬁbrous tissue or fatty inﬁltration of muscles.
Our previous studies using MAB injection in advanced stage
a-sarcoglycan mice showed poor results that improved
remarkably when host muscles were pretreated with cells
secreting metalloproteinase-9 and placenta-derived growth
factor.
30 We selected 5-month-old SCID/BlAJ because the
ﬁrst dystrophic changes are already recognizable, but fatty
inﬁltration or ﬁbrous tissue is not present yet. One of the most
important characteristics of MABs is their ability to cross the
vessel walls and colonize affected muscles in response to
different inﬂammatory signals.
31 It has been reported that
dystrophic changes in the A/J muscles appear quite late in
life and remain conﬁned to a minority of muscles, suggesting
that few inﬂammatory signals should be released.
7 Never-
theless, C57-J1 cells were able to cross the vessel walls
and massively colonize dystrophic muscles; this colonization
was further enhanced by ctx-induced muscle damage
and subsequent regeneration, even though this could not
possibly apply to a clinical situation. Nevertheless, the higher
amount of nLacZ-positive ﬁbers in ctx-pretreated muscles
suggests that inﬂammatory signals and chemoattractants
are released at higher levels after an acute damage and
consequent inﬂammation. Interestingly, we observed similar
results with adult MABs in mdx dystrophic mice (G Messina,
unpublished results). The ability to cross the vessel is of
outstanding importance to design a therapeutic strategy
in humans, as it would allow the distribution of donor cells
all over the body muscles after intra-arterial injection.
32
Moreover, signiﬁcant differences exist between skeletal
muscles from dysferlinopathy human patients and SCID/
BlAJ mice. Strong inﬂammatory inﬁltrates,
33 degenerating
and regenerating ﬁbers
34,35 are frequently recognized,
especially during the ﬁrst stage of the disease in humans,
when some cases has been misdiagnosed as inﬂammatory
myopathies.
36 This inﬂammatory activity would hypothetically
enhance the migration of MABs from the vessel to muscles in
patients but an equilibrium should be found to prevent an
Partial dysferlin reconstitution by adult murine MABs
JD ı ´az-Manera et al
8
Cell Death and Diseaseexacerbated tissue reaction against donor cells even in the
presence of immune suppression.
In conclusion, we have shown that adult murine MABs,
when transplanted into the SCID/BlAJ mice, partially restored
the expression of dysferlin to levels that allowed a normal
membrane resealing activity of single ﬁbers. These results
may lead to the ﬁrst therapeutic assays in patients affected by
muscular dystrophies secondary to dysferlin deﬁciency.
Materials and Methods
Isolation of MABs from mouse muscular biopsies. Murine MABs
were isolated from a 2-month-old C57BL/6 female as previously described.
17
Brieﬂy, both tibialis anterior were dissected and minced in 1–2mm pieces.
Fragments were selected, transferred onto collagen type I (Sigma, St. Louis, MO,
USA) coated dishes and incubated in PM consisting of Dulbecco’s modiﬁed Eagle’s
medium (DMEM) (Sigma) supplemented with 20% fetal bovine serum (Lonza,
Verviers, Belgium), 2mM L-glutamine (Sigma), 1mM sodium pyruvate (Sigma),
100 IUml
 1 penicillin and 100mgml
 1 streptomycin (Sigma), at 371C, 5% CO2
and 5% O2. After 5–7 days, the mixed cell population deriving from primary
culture outgrowth was enzymatically dissociated by collagenase/dispase treatment.
Cells obtained by dissociation were counted by Trypan blue exclusion, using a
hemocytometer, and immediately used for cloning. The cell suspension was cloned
in PM by limiting dilution in 96-multiwell dishes and incubated at 371C, 5% CO2 and
5% O2. After 7–10 days ﬁrst clones of cells were distinguishable. Once the cells
covered almost 50% of the well surface, the clones were passed and propagated in
PM. The majority of clones adopted after a few passages a large, ﬂat morphology
and underwent proliferative senescence. A few clones howevermaintained a small,
refractile, poorly adhering morphology and continued to proliferate for at least
40 passages. One of these clones, C57-J1 has been used for the experiments
here described.
In vitro differentiation assay. Spontaneous skeletal myogenic differentiation
of C57-J1 cells was induced by plating 75 10
3 cells onto reduced growth
factor Matrigel-coated dishes (Becton Dickinson Biosciences, San Jose, CA, USA).
Differentiation medium consisted of DMEM supplemented with 2% horse serum
(Sigma), 2mM L-glutamine, 1mM sodium pyruvate and 100IUml
 1 penicillin and
100mgml
 1 streptomycin. Cultures were incubated at 371C, 5% CO2 for different
periods and then processed for IF and WB analysis. The differentiation index
was calculated as the ratio between nuclei expressing myosin heavy chain (MHC)
and the total number of nuclei.
Differentiation in smooth muscle cells and osteoblasts was induced by treatment
with TGF-b (Sigma) and BMP-2 (PeproTech, Rocky Hill, NJ, USA) respectively,
and analyzed as previously described.
21 To induce differentiation in adipose cells,
we grew MABs in adipogenic-inducting medium (Lonza) for approximately 5 days,
as described previously.
17
Flow cytometry. C57-J1 cells in culture were analyzed by ﬂow cytometry
as previously reported.
16 The antibodies used for this analysis were the following:
anti-CD-44 FITC, anti-CD-34 FITC, anti-CD-45 PE, anti-CD 117-PE, anti-Flk-1-PE,
anti-Sca-1-PE (all from Becton Dickinson Biosciences) and anti-CD 31 FITC
(ID Laboratories, London, Canada).
Satellite cellcultures. SCswereisolatedfromskeletalmusclesof10-day-old
C57BL/6pups.Musclefragmentsweremechanicallyminceduntilaﬁnemixturewas
obtained. This mixture was then digested with collagenase (Sigma) and dispase
(Gibco, Paisley, UK) for 20min at 371C with gentle agitation. After the incubation,
isolated cells were collected and fragments were incubated again until the whole
tissue was digested (usually three times). Isolated cells were pooled, centrifuged
and resuspended in DMEM supplemented with 20% fetal bovine serum,
2mM L-glutamine, 1mM sodium pyruvate, 100IUml
 1 penicillin, 100mgml
 1
streptomycin, 3% chicken embryo extract, 1% gentamicin and 50nM basic FGF
(PeproTech). Contamination by nonmyogenic cell was reduced by preplating the
cell suspension onto plastic dishes where ﬁbroblasts tend to adhere more rapidly.
Differentiation was induced shifting the medium to DMEM supplemented with
5% horse serum.
Generation of scid/blAJ mice. BlAJ mice (gift from I Richard, Ge ´ne ´thon)
were bred onto the scid/scid (severe combined immune deﬁcient) strain,
homozygous for the mutation located on chromosome 16. Resulting F1
heterozygous siblings were intercrossed to obtain homozygotes for both loci:
dysf and scid.
Cell transduction with lentiviral vectors. Cells were transduced, as
previously described,
14 with third-generation lentiviral vectors expressing nLacZ.
Intramuscular delivery of MABs. All animal studies presented in this
paper were approved by the San Raffaelle Institutional Review Board. Five-month-
old BlAJ (n¼7) and SCID/BlAJ (n¼6) mice were used for intramuscular injection
of cells. When used, ctx was injected into both tibialis anterior, gastrocnemius
(25ml, 100mM) and quadriceps (50ml, 100mM), 24h before the transplantation of
cells.Previoustothetransplantation,micewereanesthetizedwithanintraperitoneal
injection of Avertin, containing tert-amyl Alcohol (2.5ml; Sigma) and 2,2,
2-tribromoethanol (2.5g; Sigma) in 100ml 0.9% saline serum. Intramuscular
delivery was performed by injection of approximately 5 10
5 C57-J1 cells,
previously transduced with lentiviral vector expressing nLacZ, into tibialis anterior,
gastrocnemius and quadriceps using a 30gauge needle. Animals were killed
1 month after the transplantation, muscles were collected and the expression of
dysferlin was analyzed by IF, real-time PCR and WB.
Intra-arterial delivery of MABs. Five-month-old SCID/BlAJ mice (n¼10)
were used for the intra-arterial delivery of the cells. All mice were trained by 1h
swimming 24h before the transplantation. When used, ctx was injected into both
tibialis anterior, gastrocnemius (25ml, 100mM) and quadriceps (50ml, 100mM),
just after the exercise. Previous to the transplantation, mice were anesthetized
with Avertin (see receipt above). For intra-arterial delivery, approximately 5 10
5
nLacZ C57-J1 cells were injected into the right femoral artery. A limited incision on
the medial upper side of the leg was performed; femoral artery was identiﬁed and
carefully isolated from femoral nerve and vein. Cells were injected by a 30gauge
needle inserted into the artery. After injection, body wall muscles and skin
were closed with sutures. Animals were killed 1 month after the injection, muscles
were collected and the expression of dysferlin was analyzed by IF, real-time PCR
and WB.
Immunoblotting. WB analysis of cells and tissues was performed as
described.
18 Antibodies used were mouse anti-dysferlin Hamlet (Novacastra,
NewcastleuponTyne,UK)at1:100dilution,mouseanti-MyoD(Dako,Carpentaria,
CA, USA) at 1:100 dilution, mouse anti-myogenin (Hybridoma Bank, Iowa City, IA,
USA) at 1:2 dilution, mouse anti-MHC (Hybridoma Bank) at 1:2 dilution, mouse
anti-GAPDH at1:5000 (Sigma) and mouse anti-b-tubulin (Covance, Princeton,
NJ, USA) at 1:5000 dilution.
Immunoﬂuorescence. Cell cultures were washed three times with PBS and
ﬁxed with 4% paraformaldehyde at 41C for 10min. Muscle samples were frozen in
liquid nitrogen cooled isopentane and serial 8-mm-thick sections were cut with a
Leica cryostat (Leica Microsystems GmbH, Wetzlar, Germany). Cells and tissue
sections were processed for IF microscopy as previously described.
12 The
antibodies used were mouse anti-dysferlin Hamlet (Novacastra) at 1:20 dilution,
rabbit anti-dysferlin (GenWay, San Diego, CA, USA) at 1:50 dilution, mouse anti-
MHC(HybridomaBank)at1:2dilution,mouseanti-Pax7(HybridomaBank)at1:2
dilution, mouse anti-MyoD (Dako) at 1:100 dilution, rabbit anti-GFP (Chemicon
International, Temecula, CA, USA) at 1:300 dilution, rabbit anti-laminin (Sigma)
at 1:300 dilution, goat anti-b-galactosidase (Biogenesis, Poole, UK) at 1:300, rat
anti-CD68(AbDSerotec,Raleigh,NC,USA)at1:100andratanti-CD3(SantaCruz
Biotechnology, Santa Cruz, CA, USA) at 1:100. The staining for X-Gal was
performed as previously described.
37
Real-time PCR. Total RNA from muscles was isolated using TRIzol protocol
(Invitrogen, Carlsbad, CA, USA). RNA (1mg) was reverse transcribed into cDNA
using the cDNA synthesis Thermoscript RT-PCR System kit (Invitrogen). Primers
used for amplify cDNA were the following: dysferlin primer: forward 50-TCC
GAAGCTAGA GGATCCAA-30; reverse 50-AGCTTCAATGGCAGCGTAGTT-30 and
murine cyclophilin: forward 50-CATACGGGTCCTGGCATCTTGTCC-30; reverse
50-TGGTGATCTTCTTGCTGGTCTTGC-30. Each cDNA sample was ampliﬁed in
triplicate using the SYBR Green supermix (Invitrogen). Student’s t-test was used
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Po0.05 as signiﬁcant.
Exerciseprotocols. Control6-month-oldSCIDmice (n¼3), nontransplanted
SCID/BlAJ mice (n¼4) and SCID/BlAJ mice transplanted with C57-J1 cells
by intra-arterial injection (n¼4) were tested for functional recovery with the
treadmill test (Columbus Instruments, Columbus, OH, USA). Transplanted
mice were tested at 21 days after the injection. Mice were adapted to the
procedure (10min every other day; 3m/min at 01 inclination) for 1 week before
beginning the exercise training protocol. For the exercise test, mice were put
into a 101 inclined treadmill at 10m/min, then the speed was increased by
2m/min every 2min until the mouse reached exhaustion, which was deﬁned
as a prolonged spending time (10s) on the shocker plate without attempting
to reengage the treadmill, or when a ﬁxed speed of 46m/min was reached.
Total distance, running time and work was registered for every mouse. Work was
calculated as the body weight (kg), gravity (9.81m/s
2), vertical speed (m/s angle)
and time (s).
Creatine kinase blood levels were analyzed 5 days before the exercise test and
6h after the exercise following manufacturer’s instruction (CK-MB detection kit;
Randox Laboratories, Crumlin, UK).
Membrane repair assay on skeletal muscle single ﬁbers. Control
dysferlin-positive SCID mice (n¼4), dystrophic, nontransplanted SCID/BlAJ (n¼4)
mice and transplanted SCID/BlAJ mice (n¼4) were used for this experiment. SCID/
BlAJmicewereused1monthaftertheintramuscularinjectionofGFP-labeledC57-J1
cells.Singleﬁberswereextractedfromgastrocnemius,extensordigitorumlongusand
tibialis anterior as previously described.
38 Fibers were washed, resuspended in
Dulbecco’sPBScontaining1mMCa
2þ (Invitrogen,Eugene,OR,USA)andmounted
onglassbottomculturedishes(MatTek,Ashland,MA,USA)inthepresenceof10mm
of the ﬂuorescent dye FM 4-64 (Invitrogen). To induce the damage, we irradiated a
7 7mmarea ofthe membraneofmuscle ﬁberswith thelasers488at50%ofpower
and 405 at 100% AOTF for 45s. Images were captured every 30s for 6min after the
irradiation.Foreveryimagetaken,theﬂuorescenceintensityvariationatthesiteofthe
damage was measured with the ImageJ imaging software (National Institute of
Health, Bethesda, MD, USA; http://rsbweb.nih.gov/ij/index.html). ANOVA test for
repeated measurements and Student’s t-test for every time acquisition were used to
identify signiﬁcant differences in the increase of light intensity. Po0.05 was
considered to be signiﬁcant.
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